Dutton Associates Announces Investment Opinion: Pluristem Therapeutics Speculative Buy Rating Maintained In Update Coverage By Dutton Associates
ROSEVILLE, Calif., Jul 30, 2008 (BUSINESS WIRE) -- Dutton Associates continues coverage of Pluristem Therapeutics (Nasdaq:PTSI) reiterating its Speculative Buy rating and a 12-month $6.50 price target. The 10-page report by Dutton senior analyst Denise T. Resnik, MS is available at www.duttonassociates.com, and at First Call, Bloomberg, Capital IQ, FactSet, Reuters, Zacks, Knobias, and other leading financial portals.
Pluristem Therapeutics is a bio-therapeutics company dedicated to the development and commercialization of cell therapy products for the treatment of a variety of severe degenerative, ischemic, and autoimmune disorders. The cell therapy products result from the Company's proprietary system to expand mesenchymal stem cells (MSCs) from post-birth human placenta. The Company's primary therapeutic area under investigation using these cells is critical limb ischemia (CLI) secondary to peripheral vascular disease (PAD). It is also investigating the use of these cells in stroke, multiple sclerosis, and inflammatory bowel disease, and, in conjunction with hematopoietic stem cells (HSCs) from human umbilical cord blood, for bone marrow transplantation (BMT). Pluristem believes its PLX (PLacenta eXpanded) cells are also potentially useful for other indications such as organ transplantation, orthopedic injuries, and the prevention of radiation sickness. Validation of Pluristem's technology is still in the preclinical stage, and we continue to believe that Pluristem has significant challenges to overcome before it can be successful. Its major challenge is to fully validate its hypothesis that the three-dimensional expansion of placental-derived mesenchymal stem cells in its PluriX(TM) 3D Bioreactor System produces therapeutic products with clear clinical benefits over existing therapies. In addition, the Company seeks to achieve 12-month milestones it has set for itself, including the initiation of its first Phase I clinical trial before the end of 2008 and the completion of the trial showing positive results.
About Dutton Associates
Dutton Associates (DA) is one of the largest independent investment research firms in the U.S. Its 30 senior analysts are primarily CFAs, and have expertise in many industries. DA provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors. The cost of enrollment in the DA one-year continuing research program is US $35,000 prepaid from the Company for 4 Research Reports, typically published quarterly, and requisite Research Notes. DA received $52,000 from the Company for 6 Research Reports with coverage commencing on 9/06/2006.
DA does not accept payment of any of its fees in company stock. Its principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures, and analyst background at www.jmdutton.com before investing.
SOURCE: Pluristem Therapeutics
CONTACT: Dutton Associates
John M. Dutton, 916/960-0623
Copyright Business Wire 2008 |
